SIGA is a debt-free, cash-rich biodefense stockpile option whose depressed valuation hinges on one decisive catalyst: renewal of the next BARDA TPOXX procurement contract.
Overview
SIGA Technologies is a commercial-stage biodefense pharmaceutical company whose value is overwhelmingly tied to TPOXX, its oral and IV antiviral for orthopoxviruses including smallpox and mpox. The U.S. government remains the dominant customer through BARDA/ASPR stockpiling for the Strategic National Stockpile, while international procurement is expanding across APAC, Europe, and MENA. TPOXX’s strong safety profile and targeted mechanism make it the preferred first-line smallpox therapeutic versus alternatives such as Tembexa, supporting a near-monopolistic role in a niche but strategically important global health security market.